Can the ex-Aragon team pull off a repeat with another new drug for mCRPC

According to an article by Alex Lash on the Xconomy web site, a start-up biotech company in South San Francisco called ORIC Pharmaceuticals will — at least initially — be highly focused on new drug therapies for men with very late-stage prostate cancer. … READ MORE …